# US 2021/0277421 A1 · Homologous Recombination Reporter Construct and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277421 A1
- Document ID: US20210277421A1
- Status: Published application
- Kind: A1
- Application number: 17/266,592
- Filed: 2019-08-06
- Published: 2021-09-09
- Earliest claimed: 2018-08-06
- Assignees: NemaMetrix Inc.
- Applicants: NemaMetrix, Inc
- Inventors: Christopher E. Hopkins; Trisha Brock; Thomas Marshall; Mary Colasanto; Zachary Stevenson
- Web page: https://patentgrep.com/patent/US20210277421A1

## CPC

- C12N 15/902: {using homologous recombination}
- C07K 14/43595: {from coelenteratae, e.g. medusae}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/8212: {Colour markers, e.g. beta-glucoronidase [GUS], green fluorescent protein [GFP], carotenoid}
- C12N 15/85: for animal cells
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides homologous recombination reporter nucleic acid construct reagents for increasing the likelihood of detecting successful modification of a specific sequence in chromosomal DNA of a host cell via homologous recombination. The homologous recombination reporter constructs contain a sequence element inserted within the coding sequence for a reporter gene resulting in a mutated reporter gene. The sequence element is removed via homologous recombination based on the presence of two homology regions present in the reporter construct.

## Claims

### Claim 1

A nucleic acid construct comprising a gene for a mutated fluorescent protein, wherein the gene comprises;
a sequence element that disrupts expression of a functional fluorescent protein and wherein the sequence element is removed with successful homologous recombination in a host cell restoring the functional fluorescent protein, wherein the sequence element comprises;
a B segment and an A′ segment, wherein the B segment comprises an expression disruption site; and,
the A′ segment comprises a direct repeat of an A segment immediately upstream of the B segment, wherein the A segment comprises a portion of a coding sequence of the fluorescent protein from 15 base pairs to 3000 base pairs in length.

### Claim 2 (depends on 1)

The construct of claim 1, wherein a translated sequence of the mutated fluorescent protein comprising the sequence element is truncated, destabilized, inactive, or produces a fluorescent signal quantitatively distinguished from a translated sequence of the functional fluorescent protein that does not comprise the sequence element.

### Claim 3 (depends on 2)

The construct of claim 2, wherein quantitatively distinguished signal comprises intensity of signal or emission signal wavelength.

### Claim 4 (depends on 1)

The construct of claim 1, wherein the A and A′ segments are 20 base pairs to 1000 base pairs in length.

### Claim 5 (depends on 1)

The construct of claim 1, further comprising one or more nuclease cleavage sites at or flanking the sequence element site.

### Claim 6 (depends on 5)

The construct of claim 5, wherein the nuclease cleavage site is recognized by nucleases selected from Cas9, Cpf1, TALen, Zinc-finger, I-Sce I, Endo.sce, HO, I-Ceu I, I-Chu I, I-Cre I, I-Csm I, I-Dir I, I-DMO I, I-Flmu I, I-Flmu II, I-Ppo I, I-Sce III, I-Sce IV, I-Tev I, I-Tev II, I-Tev III, PI-Mle I, PI-Mtu I, PI-Psp I, PI-Tli I, PI-Tli II or PI-Sce V.

### Claim 7 (depends on 1)

The construct of claim 1, further comprising two nuclease cleavage sites, one located at or near an interface between the A segment and B segment, and a second located at or near an interface between the B segment and A′ segment.

### Claim 8 (depends on 1)

The construct of claim 1, further comprising one or more specific guide RNA (sgRNA) recognition sequences.

### Claim 9 (depends on 8)

The construct of claim 8, wherein at least one of the sgRNA recognition sequences is located at or near the interface between the A segment and B segment.

### Claim 10 (depends on 8)

The construct of claim 8, further comprising a second sgRNA recognition sequence located at or near the interface between the B segment and A′ segment.

### Claim 11 (depends on 5)

The construct of claim 5, wherein the nuclease cleave site is recognized by an RNA-guided endonuclease.

### Claim 12 (depends on 1)

The construct of claim 1, further comprising one of more homology regions, wherein the regions are homologous with a region of a genome of the host cell for integration of the mutated fluorescent protein coding sequence into the genome of the host cell.

### Claim 13 (depends on 1)

The construct of claim 1, wherein the construct is not integrated into a genome of the host cell and does not comprise one or more homology regions that are homologous with a region of the genome of the host cell.

### Claim 14 (depends on 1)

The construct of claim 1, further comprising a genomic insertion sequence operably linked to the gene that expresses the mutated fluorescent protein, wherein the genomic insertion sequence and gene are located between two homology regions that are homologous with a region of a genome of the host cell.

### Claim 15 (depends on 14)

The construct of claim 14, wherein the genomic insertion sequence is an ortholog gene, or fragment thereof, of the host cell.

### Claim 16 (depends on 14)

The construct of claim 14, wherein the genomic insertion sequence, when the construct is added to the host cell, provides site directed mutagenesis of a host cell gene.

### Claim 17 (depends on 14)

The construct of claim 14, wherein the genomic insertion sequence, when the construct is added to the host cell, replaces a host ortholog at a native locus.

### Claim 18 (depends on 14)

The construct of claim 14, wherein genomic insertion sequence, when the construct is added to the host cell, disrupts expression of a host cell gene.

### Claim 19 (depends on 1)

The construct of claim 1, wherein the expression disruption site comprises a stop codon, frameshift codon, one or more point mutations, one or more destabilizing codons, protease site, sequence-encoded degradation signal, or a self cleaving peptide sequence.

### Claim 20 (depends on 1)

The construct of claim 1, wherein the B segment comprises a heterologous sequence that is stuffer nucleic acid, coding sequence for a fluorescent protein, or a non-coding sequence.

### Claim 21 (depends on 1)

The construct of claim 1, wherein the sequence element comprises one or more sgRNA sequences, an A′ segment 20 base pairs to 600 base pairs in length, a B segment comprising a stop codon, and an endonuclease cleavage at an interface between the A and B segments.

### Claim 22 (depends on 1)

The construct of claim 1, wherein the host cell is an embryo cell.

### Claim 23 (depends on 1)

The construct of claim 1, wherein the host cell is an embryo cell of a mammal, a zebrafish, a livestock animal, a farm animal, a nematode, or an avian.

### Claim 24 (depends on 1)

The construct of claim 1, wherein the host cell is a plant cell, a bacterial cell, or a yeast cell.

### Claim 25 (depends on 24)

The construct of claim 24, wherein the plant cell is a food crop plant or an agriculture plant crop.

### Claim 26 (depends on 1)

A method of increasing likelihood of detecting successful modification of a specific sequence in chromosomal DNA of a host cell via homologous recombination, comprising:
introducing a construct of claim 1 into the host cell;
introducing gene editing reagents into the host cell comprising a donor target sequence; and,
observing a desired detectable marker expressed from the construct in those host cells with successful homologous recombination gene editing.

### Claim 27 (depends on 26)

The method of claim 26, wherein the gene editing reagents comprise one of Cas9, Cpf1, TALen, Zinc-finger, I-Sce I, Endo.sce, HO, I-Ceu I, I-Chu I, I-Cre I, I-Csm I, I-Dir I, I-DMO I, I-Flmu I, I-Flmu II, I-Ppo I, I-Sce III, I-Sce IV, I-Tev I, I-Tev II, I-Tev III, PI-Mle I, PI-Mtu I, PI-Psp I, PI-Tli I, PI-Tli II or PI-Sce V nucleases.

### Claim 28 (depends on 26)

The method of claim 26, wherein the sequence element of the construct comprises all or part of at least one sgRNA recognition sequence.

### Claim 29 (depends on 26)

The method of claim 26, wherein the gene editing reagents comprise a genomic integration sequence flanked by homology regions, wherein the regions are homologous with a region of a genome of the host cell and an endonuclease.

### Claim 30 (depends on 26)

The method of claim 26, wherein the gene editing reagents comprises a sgRNA/Cas9 complex wherein the sgRNA recognizes a sgRNA recognition site on the construct.

### Claim 31 (depends on 26)

The method of claim 26, wherein the fluorescent protein coding sequence is codon optimized for the host cell.

### Claim 32 (depends on 1)

A method of increasing likelihood of detecting successful modification of a specific sequence in chromosomal DNA of a host cell via homologous recombination, comprising:
introducing a construct of claim 1 into the host cell;
introducing gene editing reagents into the host cell comprising:
Cas9 complexed with a sgRNA that binds a sgRNA recognition site on the construct;
Cas9 complexed with a sgRNA that binds a sgRNA recognition site on the chromosomal DNA; and,
a genomic insertion sequence located between two homology regions that are homologous with a region of the chromosomal DNA of the host cell; and,
observing a desired detectable marker expressed from the construct in those host cells with successful homologous recombination gene editing.

### Claim 33

An expression plasmid comprising SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 or SEQ ID NO 4.

### Claim 34

Use of a promoter for expression of a gene in a zebrafish embryo, comprising contacting the zebrafish embryo with an expression vector comprising the promotor rpl13a.

### Claim 35 (depends on 1)

A method of identifying test compounds that increase homologous recombination in a host cell, comprising:
introducing a construct of claim 1 into the host cell;
introducing gene editing reagents into the host cell;
introducing a test compound into the host cell;
observing a desired detectable marker expressed from the construct in those host cells with successful homologous recombination gene editing; and,
comparing the desired detectable signal to a control wherein the control is a host cell without a test compound and selecting those test compounds that produced an increased detectable signal in a host cell as compared to the control.

### Claim 36 (depends on 35)

The method of claim 35, wherein the gene editing reagents further comprise a donor target sequence.

### Claim 37 (depends on 35)

The method of claim 35, wherein the gene editing reagents induce double strand DNA breaks.

### Claim 38 (depends on 35)

The method of claim 35, wherein test compounds are selected from a therapeutic agent, a drug, a drug candidate, a nutritional supplemental, vitamin or food stuff.
